(AOF) – Novo Nordisk has entered into exclusive negotiations with Bio Jag, main shareholder of Biocorp, with a view to purchasing its entire stake in Biocorp, representing 45.3% of the share capital and 62.19% of the rights theoretical voting rights of Biocorp, at a price of 35 euros per share. Certain minority shareholders, representing 19.0% of the share capital and 13.07% of the theoretical voting rights of Biocorp, have undertaken to transfer their shares to Novo Nordisk following the acquisition by Novo Nordisk of the Control Block.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.